a total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan ( 0.15 mg/kg/day for seven days , followed by 0.05 mg/kg/day after recovery from the nadir of the leukocytes ) , bcnu ( 150 mg/m2 intravenously every six weeks ) or ccnu ( 100 mg/m2 orally every six weeks ) .
C0026764
multiple myeloma
C0007257
bcnu